Premium
Pargyline hydrochloride, a new antihypertensive agent
Author(s) -
Sutnick Alton I.,
Fewell J. William,
Esbenshade John H.,
Soloff Louis A.
Publication year - 1964
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196452167
Subject(s) - orthostatic vital signs , medicine , monoamine oxidase inhibitor , pargyline , supine position , blood pressure , anesthesia , constipation , antihypertensive drug , monoamine oxidase , serotonin , biochemistry , chemistry , enzyme , receptor
The nonhydrazine monoamine oxidase inhibitor, pargyline, was evaluated for antihypertensive response in 25 outpatients. Twenty‐one subjects (84 per cent) demonstrated an orthostatic fall in blood pressure, while a supine response was noted in only 12 (48 per cent). The most common and serious complication of treatment involved signs and symptoms of coronary, cerebral, and renal insufficiency. This occurred to some degree in 16 subjects (64 per cent), but in 13 merely involved symptoms of postural hypotension. In 6 of these patients the symptoms were extremely mild. Other side effects included weight gain resulting from fluid retention, increase in appetite, urinary frequency, nervousness, dryness of the mouth, and mild constipation. This agent is a potent antihypertensive drug, but is primarily effective in the erect position. Great care must be exercised in its administration because of ease of overdosage. The possibility of long‐term tolerance to the drug has not yet been evaluated.